TheraRadar
← Back
Data updated: Jun 28, 2026

AAA USA INC

Pharma

AAA USA INC is a pharmaceutical company focused on Oncology. Key products include NETSPOT.

2016
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules

FDA Novel Drug Designations

(2016-2018)
2 Novel 1 First-in-Class 1 Orphan 1 Priority Review 1 Fast Track
See 2 novel approvals →
2018 LUTATHERA (LUTETIUM LU 177 DOTATATE) First-in-Class · Orphan · Priority Review · Fast Track
2016 NETSPOT (GALLIUM DOTATATE GA-68)

AAA USA INC's Key Drugs

AAA USA INC's core commercial portfolio centers on LUTATHERA, NETSPOT, spanning Oncology — its most strategically important drugs approved in the last 15 years.

AAA USA INC's Recent FDA Approvals

New NDA/BLA approvals for AAA USA INC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

AAA USA INC's Therapeutic Areas

AAA USA INC's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 100%
2 drugs

AAA USA INC's Top Competitors

AAA USA INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

AAA USA INC Pipeline Snapshot

Active clinical trials for AAA USA INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • LUTATHERA leads revenue
  • 2 key drugs tracked

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling